Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 5/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081065 | 0.89 | JAK3 (0.39) | SYKMAP4K1KDRAURKBCDK19 | |
| SCHEMBL23080773 | 0.84 | JAK3 (0.37) | SYKBTKJAK3LCK | |
| SCHEMBL23080916 | 0.78 | MAP4K1 (0.42) | MAP4K1BTKJAK3LCK | |
| SCHEMBL18283566 | 0.76 | JAK3 (0.49) | BTKJAK3LCK | |
| SCHEMBL23081064 | 0.72 | BTK (0.40) | SYKMAP4K1BTKJAK3LCK | |
| SCHEMBL23080657 | 0.69 | JAK3 (0.47) | BTKJAK3LCK | |
| SCHEMBL20539913 | 0.68 | JAK3 (0.49) | BTKJAK3LCK | |
| SCHEMBL20540647 | 0.68 | JAK3 (0.49) | BTKJAK3LCK | |
| SCHEMBL20540720 | 0.68 | JAK3 (0.49) | BTKJAK3LCK | |
| SCHEMBL20540573 | 0.68 | JAK3 (0.49) | BTKJAK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | SYK 4/4885MAP4K1 413/4885KDR 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.